Kalehua Capital Management LLC holds a focused book of 25 stocks worth $141.3M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Veradermics Inc and trimmed Alpha Architect 1-3 MNTH Box. Their largest long position is Alpha Architect 1-3 MNTH Box at 18% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2106181/holdings"
Use Arkolith to show Kalehua Capital Management LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
82% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Alpha Architect 1-3 Month Box ETF ALPHA ARCH 1-3 | $25.4M | 218.3K | 18.0% | ▼−5.4% Reduced · −13K sh | |
| 2 | X4 Pharmaceuticals Inc COM NEW | $15.4M | 3.72M | 10.9% | —Held | |
| 3 | Surrozen Inc COM NEW | $11.2M | 385.2K | 7.9% | —Held | |
| 4 | Veradermics Inc COMMON STOCK | $9.2M | 145.7K | 6.5% | ▲New New position | |
| 5 | Relay Therapeutics Inc COM | $9.0M | 901.5K | 6.3% | —Held | |
| 6 | Sionna Therapeutics Inc COM | $7.9M | 197.1K | 5.6% | —Held | |
| 7 | Aclaris Therapeutics Inc COM | $6.9M | 1.83M | 4.9% | ▲New New position | |
| 8 | Inhibikase Therapeutics Inc COM NEW | $6.4M | 3.82M | 4.5% | ▲+118% Added · +2.1M sh | |
| 9 | Oruka Therapeutics Inc COM | $5.8M | 118.5K | 4.1% | —Held | |
| 10 | Pharvaris NV COM | $5.6M | 198.8K | 4.0% | —Held | |
| 11 | Uniqure NV SHS | $4.8M | 291.1K | 3.4% | ▲New New position | |
| 12 | Septerna Inc COM | $4.7M | 194.5K | 3.3% | —Held | |
| 13 | Compass Pathways PLC SPONSORED ADS | $4.5M | 819.7K | 3.2% | —Held | |
| 14 | LeonaBio Inc COM | $4.0M | 393.7K | 2.9% | —Held | |
| 15 | Damora Therapeutics Inc COM NEW | $3.6M | 139.0K | 2.5% | ▲New New position | |
| 16 | Gossamer Bio Inc COM | $3.4M | 10.24M | 2.4% | ▲New New position | |
| 17 | MoonLake Immunotherapeutics CLASS A ORD | $3.3M | 175.7K | 2.3% | —Held | |
| 18 | Tyra Biosciences Inc COM | $2.9M | 74.5K | 2.0% | —Held | |
| 19 | PepGen Inc COM | $1.8M | 1.00M | 1.3% | ▲New New position | |
| 20 | Instil Bio Inc COM NEW | $1.5M | 183.0K | 1.1% | ▲New New position | |
| 21 | Tenaya Therapeutics Inc COM | $1.4M | 2.00M | 1.0% | —Held | |
| 22 | Korro Bio Inc COM | $1.2M | 109.4K | 0.9% | ▲New New position | |
| 23 | Kalaris Therapeutics Inc COM | $782K | 135.6K | 0.6% | ▼−3.1% Reduced · −4K sh | |
| 24 | DiaMedica Therapeutics Inc COM NEW | $423K | 62.5K | 0.3% | ▼−34% Reduced · −33K sh | |
| 25 | Longeveron Inc COM | $361K | 347.5K | 0.3% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 27 | $141.3M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 19 | $101.1M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.